Literature DB >> 4020387

Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously.

I J Fidler, N O Brown, I R Hart.   

Abstract

Muramyl dipeptide and muramyl tripeptide in free form or encapsulated within multilamellar liposomes were injected intravenously into (C57BL/6 X C3H)F1 mice and strain 2 guinea pigs to evaluate their potential acute, subacute, or chronic toxicity. Animals received either single or multiple (X 3, X 4, X 6, X 8) injections. A definite species variation was established with regard to the toxic nature of muramyl peptides. Mice failed to exhibit any changes of a clinical, biochemical, functional, or morphological nature in response to repeated intravenous administrations of high doses of muramyl peptide (free or in liposomes). In contrast, strain 2 guinea pigs were very sensitive to muramyl peptide, regardless of the dose or number of injections, or whether it was given in liposomes or as micelles (free form). Most guinea pigs exhibited vascular pathology reminiscent of the Schwartzman phenomenon. Further toxicity studies of muramyl peptides administered at relevant biological doses are recommended, as well as studies aimed at elucidating the reasons for the species variations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4020387

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  9 in total

1.  Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.

Authors:  P M Melissen; W van Vianen; Y Rijsbergen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

Review 2.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 3.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

Review 4.  Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Authors:  Kosei Ando; Kanji Mori; Nedège Corradini; Françoise Redini; Dominique Heymann
Journal:  Expert Opin Pharmacother       Date:  2011-02       Impact factor: 3.889

5.  Review of mifamurtide in the treatment of patients with osteosarcoma.

Authors:  Leo Kager; Ulrike Pötschger; Stefan Bielack
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

6.  Treatment of Klebsiella pneumoniae septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphatidylethanolamide.

Authors:  P M Melissen; W van Vianen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

7.  Pyrimidine synthesis inhibition enhances cutaneous defenses against antibiotic resistant bacteria through activation of NOD2 signaling.

Authors:  Samreen Jatana; Craig R Homer; Maria Madajka; András K Ponti; Amrita Kabi; Francis Papay; Christine McDonald
Journal:  Sci Rep       Date:  2018-06-07       Impact factor: 4.379

Review 8.  Managing sarcoma: where have we come from and where are we going?

Authors:  Jenna S Bleloch; Reyna D Ballim; Serah Kimani; Jeannette Parkes; Eugenio Panieri; Tarryn Willmer; Sharon Prince
Journal:  Ther Adv Med Oncol       Date:  2017-09-20       Impact factor: 8.168

9.  Identification of a 7-mRNA signature as a prognostic biomarker in pediatric osteosarcoma.

Authors:  Tingting Cui; Jiantao Guo; Chunxiang Jin
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.